A newly participant in pre-OTC for biotechnology. New drug company on cell therapy, Ever Supreme (Stock No.6712) is initiated with NT$50 for IPO in the pre-OTC. RGSCTT plus the policy of "Regenerative Medical Preparations Management Regulations" are helpful in the turn out.
Chairman of Ever Supreme, Liu Chu-Chi, pointed out in the conference that the era of cell therapy has come. This year’s Nobel Prize in Physiology and Medicine was awarded to immunocytologist James P. Allison and Tasuku Honjo respectively. The two found that "CTLA-4" and "PD-1" are the keys to unscrew the bottleneck of cell therapy. He emphasized that the era of cell therapy has come, which is definitely beneficial to Ever Supreme.
Ever Supreme was established in 2016, through technology transfer of a number of cell therapy technologies from China Medical University and Academia Sinica, including dendritic cell tumor vaccine and its preparation method, stem cell treatment of brain injury and stem cell application technology transfer. Ever Supreme pipelines are divided into three: immune cell therapy of dendritic cell vaccine (ADCV), stem cell therapy of umbilical cord mesenchymal stem cells (UMSC), and chimeric antigen receptor T cells (CAR-T).
Liu Chu-Chi said that the dendritic cell vaccine for the treatment of malignant brain tumors orphans has been approved by the FDA, and the TFDA phase II clinical application is in progress; if all goes well, clinical trials can be initiated in early 2019. Ever Supreme possesses cell therapy technology, which is just right to catch the policy as the trend on multi-biotech medical industry. Ever Supreme has cooperated and negotiated with more than 10 medical facilities. Autologous cell therapy will use dendritic cells to treat malignant brain Tumors, pancreatic cancer, breast cancer, lung cancer, colorectal cancer, and ovarian cancer will be the priorities to apply. After the Taiwan FDA approval, the therapy can be officially put into treatment and is expected to bring revenue to the company in 2019.
